Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBS-007 in relapsed or refractory acute leukemia (Phase I/II, China)
CTR20254626Phase 2Active
- Sponsor
- Beijing CRO Biological Pharmaceutical Development
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of granaticin b in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by Beijing CRO Biological Pharmaceutical Development. Started May 2026; status: active.
02
Drugs
granaticin b
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20254626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254626.